Search

Displaying results 2311 - 2320 of 8469 in total
  1. Drug

    Arginine

    go.drugbank.com/drugs/DB00125
    ApprovedInvestigationalNutraceutical

    An essential amino acid that is physiologically active in the L-form.

    Mixtures: LEVAMIN PAD
  2. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414] … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

  3. Drug

    Antipyrine

    go.drugbank.com/drugs/DB01435
    Approved

    An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.

  4. Drug

    Cinnamaldehyde

    go.drugbank.com/drugs/DB14184
    Approved

    It occurs naturally in the bark of cinnamon trees and other species of the genus Cinnamomum such as camphor and cassia. Sensitivity to cinnamaldehyde may be identified with a clinical patch test.

  5. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.

  6. Drug

    Macimorelin

    go.drugbank.com/drugs/DB13074
    Approved

    They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. … Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.

  7. Drug

    Obeticholic acid

    go.drugbank.com/drugs/DB05990
    ApprovedInvestigational

    [A18696] In 2016, it was granted approval to treat primary biliary cholangitis in combination with [ursodeoxycholic acid], which was previously the mainstay treatment for this condition. … The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.[L12636]

  8. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer.

  9. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    [A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.

  10. Drug

    Brilliant green cation

    go.drugbank.com/drugs/DB11279
    ApprovedVet approved

    Brilliant green, or ethanaminium, is a derivative of triarylmethane dye that has been used as a dye to color silk and wool. … Due to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.